Gapping up
In reaction to strong earnings/guidance:
- ORGO +34%, LCII +10.4% (guides Q2 sales well above expectations), GS +4.1%, USB +2.4%
Select ETFs showing strength:
- XLE +2.5%, IWM +2.4%, XLF +2.2%, DIA +1.7%, SPY +1.2%, QQQ +0.5%
Other news:
- VBIV +18.2% (extends momentum from Tuesday regular session)
- MRNA +17.9% (confirms publication of interim results from Phase 1 study of COVID-19 vaccine candidate)
- TXMD +9.4% (TherapeuticsMD and Nurx expand access to ANNOVERA)
- PRQR +7.9% (enters into $30 mln convertible debt financing with Pontifax)
- PVH +3.9% (to streamline N American operations, includes exit from Heritage Brands)
- STNG +3.9% (reports specific insider buy transactions)
- FANG +2.5% (reports 2Q20 production; revises FY20 production guidance lower)
- ORTX +2.5% (entered into two worldwide royalty-bearing license agreements with GlaxoSmithKline (GSK))
- NVCR +2.5% (entered into a clinical trial collaboration agreement with Merck to develop Tumor Treating Fields together with MSD's anti-PD-1 therapy KEYTRUDA for treatment of non-small cell lung cancer)
- GSK +2.4% (FDA advisory committee votes in favor of positive benefit/risk profile)
- SIRI +2.1% (approves $2 bln increase to stock repurchase program)
- BDX +1.7% (announces the Government has committed to use of BD Veritor Plus system and 15-minute SARS-CoV-2 test kits)
- FSM +1.6% (reports Q2 production)
- AAPL +1.4% (The General Court of the EU annuls decision taken by the EU commission regarding the Irish tax rulings against Apple; also - target raised to $450 at Needham)
- MDT +1% (acquires Medicrea)
Analyst comments:
- GPS +6.3% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- HBI +5.3% (upgraded to Strong Buy from Mkt Perform at Raymond James; upgraded to Neutral from Underperform at BofA Securities), ALLY +4.6% (upgraded to Overweight from Neutral at JP Morgan)
- HRB +4.4% (upgraded to Buy from Neutral at Northcoast)
- PUMP +4.3% (upgraded to Outperform from Market Perform at Cowen)
- HAL +3.4% (upgraded to Outperform from Market Perform at Cowen)
- SLB +3% (upgraded to Outperform from Market Perform at Cowen)
- MT +2.8% (initiated with a Buy at Goldman)
- HOG +2.7% (upgraded to Buy from Neutral at UBS)
- AR +2.6% (upgraded to Neutral from Sell at MKM Partners)
- WFC +2.5% (upgraded to Outperform from In-line at Evercore ISI)
- TDY +2.2% (upgraded to Buy from Hold at Jefferies)
- NMIH +1.9% (upgraded to Overweight from Neutral at JP Morgan)